Investor Information

Verweise

  1. Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez, H, Wiese, T & Morrissey, B. A multicenter randomized control trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018;198(9), 1151-1164, and data on file at Pulmonx.
  2. Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017;196(12), 1535-1543.
  3. Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016;194(9), 1073-1082, and data on file at Pulmonx.
  4. Klooster, K, ten Hacken, NH, Hartman, JE, Kerstjens, HA, van Rikxoort, EM & Slebos, DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med, 2015;373(24), 2325-2335.
  5. Klooster, K, Hartman, JE, ten Hacken, NH, Slebos, DJ. One-year follow-up after endobronchial valve treatment in patients with emphysema without collateral ventilation treated in the STELVIO trial. Respir 2017; 93(2), 112-121.
  6. Koster, T. David et al. Predicting lung volume reduction after endobronchial valve therapy is maximized using a combination of diagnostic tools. Respir, 2016;92.3, 150-157, and data on file at Pulmonx.
  7. Ruwwe-Glösenkamp, C, Dorothea, T, Döllinger, F, Temmesfeld-Wollbruck, TW, Hippenstiel, S, Norbert, S & Huebner, RH. Characterization of Chartis Phenotypes based on fissure completeness scores. Eur Respir J, 2018.
  8. Mansfield C, Sutphin J, Shriner K, Criner GJ, Celli BR. Patient preferences for endobronchial valve treatment of severe emphysema. Chronic Obstr Pulm Dis. 2019;6(1). doi: https://doi.org/10.15326/jcopdf.6.1.2018.0147
  9. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017. Available from: http://goldcopd.org.
  10. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. Available from: http://goldcopd.org.
  11. NICE (National Institute for Health and Care Excellence) Final Guidance on Endobronchial valve insertion to reduce lung volume in emphysema (https://www.nice.org.uk/guidance/ipg600), accessed Dec. 20, 2017.
  12. German Respiratory Society (DGP) and Austrian Respiratory Society (OGP) Vogelmeier, C, Buhl, R, Burghuber, O, Criee, CP, Ewig, S, Godnic-Cvar, J, & Nowak, D. Guideline for the diagnosis and treatment of COPD patients-issued by the German respiratory society and the German Atemwegsliga in cooperation with the Austrian Society of Pneumology. Pneumologie (Stuttgart, Germany), 2018;72(4), 253-308.
  13. National Health Care Institute of the Netherlands: Richtlijn Ketenzorg COPD. Dekhuijzen, PNR, Smeele, IJM, Smorenburg, SM, and Verhoeven, MAWM. 2005. Leusden, Stichting Ketenkwaliteit COPD.
  14. Lakerveld-Heyl, K, RMM, Geijer, R, Gosselink, J, Muris, MA, Vermeeren, W Van Hensbergen, MCE, Verhoef-van Wijk, S, Flikweert, & CD, Van Ravensberg, 2007. 104 Landelijke Eerstelijns Samenwerkings Afspraak COPD. Huisarts en Wetenschap 50:S21-S27.
  15. van Agteren, JE, Hnin, K, Grosser, D, Carson, KV & Smith, BJ. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. The Cochrane Library, 2017.
  16. Davey, C, Zoumot, Z, Jordan, S, McNulty, WH, Carr, DH, Hind, MD, Shah, PL. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet, 2015;386(9998), 1066-1073.
  17. Sciurba, FC, Ernst, A, Herth, FJ, Strange, C, Criner, GJ, Marquette, CH, McLennan, G. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med, 2010;363(13), 1233-1244.
  18. Slebos, DJ, Shah, PL, Herth, FJ & Valipour, A. Endobronchial valves for endoscopic lung volume reduction: best practice recommendations from expert panel on endoscopic lung volume reduction. Respir, 2017;93(2), 138-150.
  19. Herth, FJ, Noppen, M, Valipour, A, Leroy, S, Vergnon, JM, Ficker, JH & Ernst, A. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Euro Respir J, 2012;39(6), 1334-1342.
  20. Granted breakthrough device status (formerly known as the Expedited Access Pathway, or EAP) on May 4, 2017, Summary of Safety and Effectiveness document for the Pulmonx Zephyr Valve system (https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180002B.pdf).
  21. Raherison, C, & Girodet, PO. Epidemiology of COPD. Euro Respir Review, 2009;18(114), 213-221.
  22. Quaderi, SA & Hurst, JR. The unmet global burden of COPD. Glob Health Epidemiol Genom,2018; doi:10.1017/gheg.2018.
  23. Habraken, JM, ter Riet, G, Gore, JM, Greenstone, MA, Weersink, EJ, Bindels, PJ, & Willems, DL. Health-related quality of life in end-stage COPD and lung cancer patients. J Pain Symptom Manage, 2009;37(6), 973-981.
  24. Wilson, L, Devine, EB, & So, K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med, 2000;94(3), 204-213.
  25. Ford, ES, Murphy, LB, Khavjou, O, Giles, WH, Holt, JB, & Croft, JB. Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest, 2015;147(1), 31-45 and Pulmonx analysis.
  26. Soriano, JB, Abajobir, AA, Abate, KH, Abera, SF, Agrawal, A, Ahmed, MB, Alam, N. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017; 5(9), 691-706.
  27. Wheaton, AG, Cunningham, TJ, Ford, ES, Croft, JB. Employment and activity limitations among adults with chronic obstructive pulmonary disease—United States, 2013. MMWR Morb Mortal Wkly Rep, 2015;64(11), 289.
  28. Ford, ES, Murphy, LB, Khavjou, O, Giles, WH, Holt, JB, Croft, JB. Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest, 2015; 147(1), 31-45.
  29. Casanova, C, Cote, C, De Torres, JP, Aguirre-Jaime, A, Marin, JM, Pinto-Plata, V, Celli, BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2005;171(6), 591-597.
  30. National Center for Health Statistics. Summary health statistics: National Health Interview Survey, 2018.
  31. Soriano, JB., Lamprecht, B, Ramirez, AS, Martinez-Camblor, P, Kaiser, B, Alfageme, I. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med, 2015; 3: 443-50. BMC Pulm Med, 14, 163.
  32. Wilson, DO, Weissfeld, JL, Balkan, A, Schragin, JG, Fuhrman, CR, Fisher, SN, Sciurba, FC. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med, 2008;178(7), 738-744.
  33. Tian, Q, Qi, F, An, Y, Liu, XC, Chen, LA. Using the Chartis system to selectively target a lung segment with a persistent air leak. Euro Respir J, 2013;41(6), 1461-1463.
  34. NICE (National Institute for Health and Care Excellence) Chronic obstructive pulmonary disease in over 16s: diagnosis and management (https://www.nice.org.uk/guidance/NG115), accessed February 27, 2020.